Skip to main content
Olema Pharmaceuticals, Inc. logo

Olema Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · OLMA ISIN · US68062P1066 US Manufacturing
Open in API
Filings indexed 506 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country US United States of America
Listing US OLMA

About Olema Pharmaceuticals, Inc.

https://olema.com/

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers. The company concentrates on endocrine-driven diseases, with a primary emphasis on breast cancer. Its lead product candidate, palazestrant (OP-1250), is an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD). Palazestrant is under investigation in clinical trials as a potential treatment for patients with ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is advancing a pipeline of drug candidates with the goal of developing improved therapeutic options for cancer patients.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 80% confidence The document is a Form 8-K “Current Report” filed with the SEC under the Securities Exchange Act of 1934. It announces the entry into a clinical trial collaboration agreement and furnishes a press release as an exhibit. It does not present financial statements itself (beyond referring to regulatory disclosures), nor does it fit specific categories like a financing update, management change, or dividends. Therefore, it best fits the fallback category for general regulatory announcements and filings (RNS).
2026-05-26 English
8-K
Regulatory Filings Classification · 94% confidence The document is an SEC Form 8-K “Current Report” filed under Section 13/15(d) of the Exchange Act reporting Regulation FD disclosure and furnishing a press release as Exhibit 99.1. It contains clinical data and forward‐looking statements but no financial statements or detailed management analysis. This is a general regulatory filing rather than an earnings release, proxy, or other specific report type. Therefore, it falls under the Regulatory Filings category (RNS).
2026-05-21 English
10-Q - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-12 English
8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
Regulatory Filings Classification · 92% confidence The document is a U.S. SEC Form 8-K “Current Report” filing detailing Item 2.02 (Results of Operations and Financial Condition) and furnishing a press release as Exhibit 99.1. It does not itself contain the earnings text but is the regulatory filing that references the press release. Under our taxonomy, a standalone SEC Form 8-K is a general regulatory announcement and falls into the Regulatory Filings (RNS) category rather than the Earnings Release (ER) category (since the actual release text isn’t embedded).
2026-05-12 English
8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive lease agreement, including detailed terms of the lease and obligations. It does not contain financial statements or quarterly/yearly financial results, nor is it an earnings release or annual report. It is not a management or board change announcement, nor a voting result or proxy solicitation. The document is a regulatory filing reporting a material contract event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2026-05-01 English
SCHEDULE 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
Major Shareholding Notification
2026-03-20 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.